Stock Events

Stock Events

Achilles Therapeutics 

$1.48
24
+$0.01+0.68% Thursday 19:57

Statistics

Day High
1.5
Day Low
1.45
52W High
1.51
52W Low
0.63
Volume
1,204,120
Avg. Volume
1,291,847
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.61
-0.51
-0.42
-0.32
Expected EPS
-0.46
Actual EPS
-0.46

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
0Revenue
-69.67MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACHL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Achilles Therapeutics' cell therapy approach for cancer treatment.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the innovative treatment space including cancer.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the CRISPR gene editing sector, offering potential competitive technologies for cancer therapy.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, which are in direct competition with Achilles' autologous cell therapy approach.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a major player in the cell therapy space for cancer, competing with Achilles' therapies.

About

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Iraj Ali Ph.D.
Employees
204
Country
GB
ISIN
US00449L1026

Listings

0 Comments

Share your thoughts

FAQ

What is Achilles Therapeutics stock price today?▼
The current price of ACHL is $1.48 USD — it has increased by +0.68% in the past 24 hours. Watch Achilles Therapeutics stock price performance more closely on the chart.
What is Achilles Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Achilles Therapeutics stocks are traded under the ticker ACHL.
What were Achilles Therapeutics earnings last quarter?▼
ACHL earnings for the last quarter are -0.46 USD per share, whereas the estimation was -0.46 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Achilles Therapeutics revenue for the last year?▼
Achilles Therapeutics revenue for the last year amounts to 0 USD.
What is Achilles Therapeutics net income for the last year?▼
ACHL net income for the last year is -69.67M USD.
How many employees does Achilles Therapeutics have?▼
As of April 03, 2026, the company has 204 employees.
In which sector is Achilles Therapeutics located?▼
Achilles Therapeutics operates in the Health Care sector.
When did Achilles Therapeutics complete a stock split?▼
Achilles Therapeutics has not had any recent stock splits.
Where is Achilles Therapeutics headquartered?▼
Achilles Therapeutics is headquartered in London, GB.